SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
MoonLake Immunotherapeutics (MLTX) has a negative trailing P/E of -5.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 6.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -19.23%, forward earnings yield 14.58%.
Criteria proven by this page:
- VALUE (88/100, Pass) — analyst target implies upside (+34.5%).
- Forward P/E 6.9 — analysts expect a return to profitability with estimated EPS of $2.74 for FY2030.
- Trailing Earnings Yield -19.23% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 14.58% as earnings recover.
- Analyst consensus target $25.25 (+34.5% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
88/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MLTX
Valuation Multiples
P/E (TTM)-5.2
Forward P/E6.9
PEG RatioN/A
Forward PEGN/A
P/B Ratio3.88
P/S Ratio0.00
EV/EBITDA-4.8
Per Share Data
EPS (TTM)$-3.53
Forward EPS (Est.)$2.74
Book Value / Share$4.72
Revenue / Share$0.00
FCF / Share$-3.04
Yields & Fair Value
Earnings Yield-19.23%
Forward Earnings Yield14.58%
Dividend Yield0.00%
Analyst Target$25.25 (+34.5%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
-1,853.1 |
0.00 |
1.50 |
0.00 |
- |
| 2021 |
-6.8 |
0.00 |
-31.36 |
0.00 |
- |
| 2022 |
-6.2 |
-0.12 |
6.30 |
0.00 |
- |
| 2023 |
-82.4 |
1.23 |
5.98 |
0.00 |
- |
| 2024 |
-28.6 |
-0.18 |
7.62 |
0.00 |
- |
| 2025 |
-3.7 |
-0.04 |
2.79 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$-0.01 |
$0.00 |
$-90.84K |
- |
| 2021 |
$-6.84 |
$0.00 |
$-53.64M |
- |
| 2022 |
$-2.20 |
$0.00 |
$-64.51M |
- |
| 2023 |
$-0.73 |
$0.00 |
$-36.01M |
- |
| 2024 |
$-1,919.51 |
$0.00 |
$-120.68M |
- |
| 2025 |
$-3.53 |
$0.00 |
$-227.32M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-3.65 |
$-4.43 – $-2.84 |
$0.00 |
$0.00 – $0.00 |
8 |
| 2027 |
$-3.63 |
$-4.37 – $-2.61 |
$22.14M |
$15.93M – $30.93M |
9 |
| 2028 |
$-2.59 |
$-4.77 – $-0.86 |
$137.91M |
$99.25M – $192.69M |
8 |
| 2029 |
$-0.48 |
$-0.72 – $-0.30 |
$452.91M |
$325.92M – $632.8M |
6 |
| 2030 |
$2.74 |
$1.74 – $4.15 |
$897.34M |
$645.75M – $1.25B |
6 |
